| Literature DB >> 26500469 |
Tânia Pereira1, Carlos Correia1, João Cardoso1.
Abstract
The great incidence of cardiovascular (CV) diseases in the world spurs the search for new solutions to enable an early detection of pathological processes and provides more precise diagnosis based in multi-parameters assessment. The pulse wave velocity (PWV) is considered one of the most important clinical parameters for evaluate the CV risk, vascular adaptation, and therapeutic efficacy. Several studies were dedicated to find the relationship between PWV measurement and pathological status in different diseases, and proved the relevance of this parameter. The commercial devices dedicate to PWV estimation make a regional assessment (measured between two vessels), however a local measurement is more precise evaluation of artery condition, taking into account the differences in the structure of arteries. Moreover, the current devices present some limitations due to the contact nature. Emerging trends in CV monitoring are moving away from more invasive technologies to non-invasive and non-contact solutions. The great challenge is to explore the new instrumental solutions that allow the PWV assessment with fewer approximations for an accurately evaluation and relatively inexpensive techniques in order to be used in the clinical routine.Entities:
Keywords: Arterial stiffness; Commercial devices; Measurement methods; Non-invasive methods; Pulse wave velocity
Year: 2015 PMID: 26500469 PMCID: PMC4609308 DOI: 10.1007/s40846-015-0086-8
Source DB: PubMed Journal: J Med Biol Eng ISSN: 1609-0985 Impact factor: 1.553
Studies of PWV carotid–femoral measurement and reference values
| Feature population/disease | Number of subjects | Age (years ± SD) | PWV (m s−1) | Devices | References |
|---|---|---|---|---|---|
| Healthy | 15 | 33 ± 3 | 8.9 ± 0.3 | Pulse transducer probe (Siemens Elema AB) synchronism with ECG | Isnard et al. [ |
| Hypertensive subjects | 16 | 38 ± 3 | 11.8 ± 0.5 | ||
| Healthy | 418 | 46 ± 12 | 0.07 × SP + 0.09 × age − 4.3 | TY-360 pressure transducer (Fukuda Co.) | Asmar et al. [ |
| Normotensive subjects | 124 | 45 ± 13 | 8.5 ± 1.5 | Doppler unit (SEGA-M842, Oregon, USA) synchronism with ECG | Asmar et al. [ |
| Untreated hypertensive patients | 224 | 48 ± 11 | 11.8 ± 2.7 | ||
| Treated hypertension patients | 164 | 59 ± 11 | 10.1 ± 2.6 | ||
| Hypertensive without atherosclerosis | 530 | 57 ± 13 | 12.4 ± 2.6 | Complior® | Blacher et al. [ |
| Hypertensive with atherosclerosis | 180 | 67 ± 12 | 14.9 ± 4.0 | ||
| Hypertensive without vascular disease | 196 | 57 ± 13 | 12.4 ± 2.7 | Complior® | Bortolotto et al. [ |
| Hypertensive with vascular disease | 40 | 62 ± 13 | 14.3 ± 4.0 | ||
| Subjects >70 years | 141 | 87.1 ± 6.6 | 14.15 ± 3.11 | Complior® | Meaume et al. [ |
| Hypertensive patients | 1980 | 50 ± 13 | 11.5 ± 63.4 | Pulse transducer probes (electronics for medicine) | Laurent et al. [ |
| Hypertensive without CV events | 948 | 50 ± 12 | 11.4 ± 3.1 | Pulse transducer probes (electronics for medicine) | Boutouyrie et al. [ |
| Hypertensive with CV events | 97 | 56 ± 13 | 12.8 ± 3.2 | ||
| Female | 800 | 53.5 | 10.8 ± 3.2 | Two piezoelectric pressure transducers (Hellige GmbH) | Willum-Hansen et al. [ |
| Male | 878 | 54.3 | 11.8 ± 3.6 | ||
| Female | 1127 | 37 | 7.4 | Complior®, SphygmoCor®, PulsePen® | Vermeersch et al. [ |
| Male | 1080 | 39 | 8.2 | ||
| Smoker | 444 | 43 | 8.0 | ||
| No smoker | 2207 | 38 | 7.8 | ||
| General population (52 % hypertensive, 11 % diabetic, 17 % smokers) | 2200 | 46.33 ± 13.77 | 10.05 ± 2.03 | Complior® | Maldonado et al. [ |
Studies of local PWV measurement and reference values
| Feature population/disease | Number of subjects | Age (years ± SD) | PWV (m s−1) | Devices | References |
|---|---|---|---|---|---|
| Cardiac patients | 18 | 34 ± 2 | 6.68 ± 0.32 | Catheter (Millar Mikro-Tip, Millar Instruments, Houston, Texas) | Murgo et al. [ |
| Cardiac patients | 9 | 42 ± 5 | 4.4 ± 0.4 | Catheter (Millar PC-786(K)) | Latham et al. [ |
| Cardiac patients | 107 | 60.49 ± 8.31 | 8.78 ± 2.24 | Catheter (6 Fr right Judkins catheter) | Podolec et al. [ |
| Healthy | 21 | 23–74 | 4–9 | Ultrasound (GE Vingmed Ultrasound, Horten, Norway) | Rabben et al. [ |
| Healthy | 16 | 55 ± 7 | 5.65 ± 0.75 | MRI (Gyroscan ACS/NT15, Philips, Best, The Netherlands) | Van der Meer et al. [ |
| Type 2 diabetes mellitus | 14 | 55 ± 8 | 6.83 ± 1.60 |
Devices and methods used to determine arterial stiffness
| Methods | Measurements | Devices |
|---|---|---|
| Non-invasive | Regional PWV | PulsePen® |
| Complior® | ||
| SphygmoCor® | ||
| Ultrasound | ||
| Local PWV | Magnetic resonance image | |
| Ultrasound | ||
| Invasive | Local PWV | Angiography |
Adapted from [52]
Advantages and disadvantages of methods to PWV measurement
| Methods | Advantages | Disadvantages |
|---|---|---|
| Imaging | Direct measurement of the path length | Expensive technology |
| Non-imaging | More affordable (less expensive) and validated technology | Error associated with distance estimation, distortion in the acquisition signal, problems to access the signal in obese people, only allows a regional assessment |
| Optical | Low cost technology, measurement without contact, capability to acquire the signal in obese persons | Early stage of validation |